As reported in the ISPAD Clinical Practice Consensus Guidelines 2022 [8], T1D is, in fact, characterized by four stages: Stage 1 is identified by the presence of multiple islet autoantibodies, normal blood glucose, and no clinical symptoms; Stage 2 has multiple islet autoantibodies, abnormal glucose tolerance, and usually no symptoms; Stage 3 has multiple islet autoantibodies, blood glucose above ADA diagnostic thresholds, and presence of clinical symptoms; and Stage 4 is identified by the presence of established, long-standing T1D. The gene discussed is ADA; the disease is type 1 diabetes mellitus.